DexCom, Inc. $DXCM Shares Acquired by Profund Advisors LLC

Profund Advisors LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,655 shares of the medical device company’s stock after buying an additional 3,829 shares during the period. Profund Advisors LLC’s holdings in DexCom were worth $3,025,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Andra AP fonden acquired a new position in DexCom during the 2nd quarter valued at about $26,000. Zions Bancorporation National Association UT bought a new position in shares of DexCom in the first quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the second quarter valued at $45,000. Anderson Financial Strategies LLC acquired a new position in shares of DexCom during the first quarter valued at $37,000. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of DexCom during the second quarter valued at about $70,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,383 shares of company stock worth $434,274 over the last three months. 0.32% of the stock is owned by insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $55.00 on Monday. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The stock has a fifty day moving average of $69.24 and a 200-day moving average of $77.72. The company has a market capitalization of $21.45 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the firm earned $0.45 earnings per share. DexCom’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on DXCM. Wells Fargo & Company set a $93.00 target price on shares of DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Citigroup lowered their price objective on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Oppenheimer downgraded DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Robert W. Baird set a $82.00 price target on DexCom in a research report on Friday, October 31st. Finally, Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $88.86.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.